Beam Therapeutics Inc. (BEAM)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 66.09 |
| Open | 66.76 |
| Bid | 68.68 x 1200 |
| Ask | 70.00 x 800 |
| Day's range | 66.00 - 69.95 |
| 52-week range | 27.77 - 116.91 |
| Volume | |
| Avg. volume | 1,318,790 |
| Market cap | 4.86B |
| Beta (5Y monthly) | 1.76 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.59 |
| Earnings date | 07 Nov 2022 - 11 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 92.27 |
- Zacks
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Tops Revenue Estimates
Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 5.56% and 26.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
Even after rising 8.2% this past week, Beam Therapeutics (NASDAQ:BEAM) shareholders are still down 40% over the past year
Beam Therapeutics Inc. ( NASDAQ:BEAM ) shareholders will doubtless be very grateful to see the share price up 78% in...
- Motley Fool
Why Beam Therapeutics Stock Dipped Today
Beam Therapeutics (NASDAQ: BEAM), a pre-clinical gene-editing company, saw its shares dip by as much as 9.8% in early morning trading Monday. Ahead of the opening bell, Beam announced that the Food and Drug Administration (FDA) placed a clinical hold on its relapsed/refractory T-cell acute lymphoblastic leukemia candidate known as BEAM-201. Beam didn't provide a reason for the clinical hold in its early morning press release.
© 2022 Yahoo. All rights reserved.
